Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding as Renovaro AI. The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren, and Ruud Hendriks.
Leni Boeren brings a 40-year career in the financial sector, with banking roles at Paribas and Rabobank. She has held several director-level positions at Amsterdam Exchanges and Euronext, the first pan-European stock and derivatives exchange resulting from the merger of exchanges in Amsterdam, Paris, and Brussels. After these roles, she transitioned to asset management, spending over a decade undertaking executive roles, including CEO and Chair of the international Robeco Groep N.V. and holding board of directors seats for the group’s subsidiaries. Boeren currently holds several advisory roles, including the Capital Market Committee of the Dutch regulator, the Authority for the Financial Markets.
Boeren said she was excited to join the Board for Renovaro Biosciences as it moves towards combining with GEDiCube. “I look forward to supporting the company in unlocking the vast potential of the two companies. Together, we are committed to spearheading advancements in the battle against cancer and other diseases, harnessing cutting-edge AI technology and pioneering biotherapeutics,” Boeren added (https://ibn.fm/o1anO).
Ruud Hendriks brings over 35 years of experience in asset management, having held senior roles at some of the most established financial institutions. This includes a decade at Goldman Sachs Asset Management, which he joined as a managing director, becoming co-head of sales for Europe, the Middle East, and Africa. Before this, he worked at Robeco Group, including Rodamco, the property fund of the Robeco Group, before becoming Senior Vice President and Global Head of Institutional Sales at Robeco. He also advises wealthy individuals next to being an Ambassador to Add Value Fund Management B.V.
Avram Miller is an American businessperson, corporate venture capitalist, scientist, and technologist who served as vice president of Business Development for Intel Corporation and co-founded Intel Capital, a division of Intel Corporation set up to manage corporate venture capital, global investment, mergers, and acquisition. Before his career in High-Tech, he had a 13-year career in medical science. For the last decade, Miller has re-engaged his interest in utilizing technology in health care, advising prominent institutions like the Cleveland Clinic and Sheba Medical Center coaching and investing in many early-stage Med-Tech startups.
Most importantly, according to Miller, the impact of AI on medicine will be as significant as the impact of the Internet on the computer industry. “I was fortunate to play a role in that, and now I am excited to have a similar opportunity. We are at an inflection point. AI should lead to personalized medicine comprised of new diagnostics and treatments, which will have a profound impact on longevity and, in particular, health span, something I care deeply about,” Miller added (https://ibn.fm/CW1pe). “I believe that Renovaro Bioscience, combined with GEDiCube, has the key elements to play a significant role in this transformation. I am delighted to have the opportunity to assist the company as a board member and an advisor working closely with the company’s leadership team.”
For more information, visit the company’s website at www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Approximately 20% of people in the U.S. live in a rural area, and they face…
On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…
Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…
Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…
Many existing cancer treatments, such as chemotherapy and radiation, don’t distinguish between cancer cells and…
A study whose findings were recently published has provided insights into the cost of treating…